Mazdutide Purity: 136 Lab Tests Across 65 Identified Manufacturers
42 studies on Mazdutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 136 published third-party lab tests of Mazdutide across 65 identified manufacturers. Among reports with a positive numeric purity result, the average is 99.37%. Within this published corpus, 0 positive purity results were below 90%, and 7 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
Mazdutide average prices
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $34.00 | $34.00–$34.00 | $3.40 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
We tested 136 Mazdutide batches across 65 identified manufacturers
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 23 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Top 3 vendor evidence profiles for Mazdutide
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 9 | 99.54% | 0 of 9 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #2 | 6 | 99.43% | 0 of 6 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → | |
| #3 | 5 | 99.67% | 0 of 5 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #99863 (99.26%) · #100108 (99.37%) · #81937 (99.62%) · #76016 (99.64%) · #69663 (99.2%) · #51583 (99.88%)
Mazdutide studies and clinical research
-
Randomized trial investigates Mazdutide's efficacy for prediabetes reversal in Chinese adults
If successful, this trial could establish **Mazdutide** as a novel and effective pharmacological strategy for **prediabetes reversal**, offering a significant advancement beyond current lifestyle-focused interventions…
-
Mazdutide trial to assess coronary plaque progression in overweight/obese patients with atherosclerosis
If successful, this trial could establish **mazdutide** as a novel therapeutic strategy for directly mitigating **coronary atherosclerosis** progression in patients with **overweight** or **obesity**, beyond its known…
-
GLP-1RA Adjuvant Therapy Post-Bariatric Surgery Investigated for Efficacy and Safety in Chinese Obesity Patients
A study investigates the efficacy and safety of adjuvant GLP-1 receptor agonist therapy combined with bariatric surgery in Chinese patients with obesity.
-
Mazdutide, a Dual GLP-1/Glucagon Agonist, Achieves Substantial Weight Loss in Non-Diabetic Obese Adults
**Mazdutide**'s dual `GLP-1` and `glucagon receptor agonism` offers a potent new strategy for managing **obesity** and improving metabolic health, particularly for non-diabetic individuals. This evidence reinforces it…
-
Mazdutide 9mg achieves 16.65% body weight reduction in Chinese adults with obesity over 60 weeks
**Mazdutide 9mg** demonstrates a potent new therapeutic option for **obesity** management, particularly relevant for Chinese adults. The substantial **16.65%** mean weight loss and high responder rate (over **84%** ac…
-
Mazdutide 9 mg achieves 81.7% weight reduction ≥5% in Chinese adults with obesity
This study provides compelling evidence that **mazdutide 9 mg** is a highly effective option for weight management in Chinese adults with obesity, offering a significant improvement over previous lower doses. For indi…
-
GLP-1 Receptor Agonists Show Promise for Alcohol Use Disorder Treatment by Modulating Brain Reward Pathways
**GLP-1 receptor agonists (GLP-1RAs) represent a promising new class of drugs for Alcohol Use Disorder (AUD)**, offering a novel mechanism beyond existing treatments. For individuals struggling with AUD, this research…
-
GLP-1/GCG Dual Agonist Explored for Diabetes-Related Early Dementia
This study is critically important because it addresses a significant unmet medical need for effective treatments for cognitive dysfunction in individuals with type 2 diabetes, a population at high risk for dementia. …
-
IBI362 Shows Promise in Phase III Trial for Obesity and Overweight
The GLORY-1 study successfully completed its 48-week double-blind treatment period, evaluating the efficacy and safety profiles of IBI362 at two distinct doses against placebo. While specific numerical results regardi…
-
New Drug Mazdutide Explored as Post-Surgery Aid for Severe Obesity
-
Mazdutide Plus Lifestyle Intervention Trial for Obesity Weight Management
This RANDOMIZED, QUADRUPLE, TREATMENT trial is currently RECRUITING participants, with an estimated completion in December 2028, meaning no results are available yet. The study is meticulously designed to investigate …
-
New Drug IBI362 Challenges Semaglutide for Diabetes and Obesity
As an active Phase 3 study with an estimated completion date of June 2026, specific efficacy and safety results comparing IBI362 and Semaglutide are not yet available. The study is designed to assess the non-inferiori…
-
IBI362 Safety and Drug Levels Explored in Obese Chinese Adolescents
The successful completion of this Phase 1 trial is a significant step towards developing a potential new treatment for adolescent obesity. Given the rising prevalence of obesity in young populations and the limited th…
-
IBI362 Phase 1/2 Study Evaluates Safety and PK/PD in Overweight and Obesity
The successful completion of this Phase 1/2 study marks a critical developmental milestone for IBI362 as a potential therapeutic agent for overweight and obesity. Establishing the initial safety profile and understand…
-
Comparing Drug Efficacy for Weight Loss in Adults Without Diabetes
This comprehensive review provides crucial evidence for clinicians to make informed decisions when prescribing pharmacological interventions for weight management in non-diabetic adults. The significant weight loss ob…
-
Exercise Boosts Betaine to Rejuvenate Systemic Aging in Mammals
This research provides a crucial molecular link between exercise and its anti-aging benefits, identifying betaine as a key mediator. The finding that betaine acts as a 'beneficial mimetic' for long-term exercise is pa…
-
First-in-Human Study Assesses Safety and PK/PD of Novel Compound LY3305677
The successful completion of this Phase 1 study is a critical milestone, as it provides the foundational safety and pharmacokinetic data necessary for advancing LY3305677 into further clinical development. Understandi…
-
IBI362 vs. Dulaglutide: A Phase 3 Trial for Type 2 Diabetes
If IBI362 demonstrates superior or comparable efficacy with a favorable safety profile against dulaglutide, it could represent a significant advancement in Type 2 Diabetes management. This would provide a new therapeu…
-
Massive Chinese Registry to Track Real-World Obesity Management and Outcomes
This large-scale registry is crucial for understanding the current state of obesity and Type 2 Diabetes Mellitus management in China, a region with unique dietary and lifestyle factors. The real-world data collected w…
-
HDM1005 vs. Mazdutide: New Phase 3 Trial for Type 2 Diabetes
The development of HDM1005 represents a potential new therapeutic avenue for patients with T2DM who struggle with current treatment regimens. If HDM1005 demonstrates superior efficacy or a better safety profile compar…
-
IBI362 vs. Semaglutide for Fatty Liver Disease in Overweight Chinese Adults
The successful completion of this Phase III trial could establish IBI362 as a novel and effective treatment option for MAFLD, a condition with limited approved pharmacotherapies. Given the high prevalence of MAFLD in …
-
IBI362's Safety and Drug Profile Explored in Type 2 Diabetes Patients
The successful completion of this early-phase trial is a significant step forward for IBI362, a novel therapeutic candidate for Type 2 Diabetes. This foundational data on its human safety, tolerability, and drug profi…
-
Mazdutide vs. Semaglutide: Phase 3 Trial Design for Diabetes and Obesity
This detailed trial design and baseline data publication is crucial as it lays the groundwork for understanding the potential of Mazdutide as a significant new therapeutic option. If Mazdutide demonstrates superior or…
-
Once-Weekly Mazdutide Shows Significant Weight Loss in Obesity and Overweight
The substantial and clinically meaningful weight loss achieved with once-weekly Mazdutide positions it as a highly promising therapeutic agent for obesity and overweight. The dual agonism of GLP-1 and GIP receptors ap…
-
China's Obesity Epidemic: Current Status, Progress, and Future Challenges
This review critically highlights the urgent need for more effective, scalable, and culturally appropriate public health interventions in China. Understanding the specific drivers of the epidemic and the gaps in curre…
-
Mazdutide, a Novel Dual Agonist, Gains First Approval for Weight Loss and Diabetes
The first approval of Mazdutide in China is a pivotal development, introducing a novel dual glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R) agonist to the therapeutic landscape. This provides a …
-
Mazdutide Dual Agonist Shows Promise for Adolescent Obesity, Diabetes, and Hyperuricemia
This case report provides crucial preliminary evidence supporting the potential of Mazdutide as a comprehensive treatment option for adolescents grappling with the complex interplay of obesity, type 2 diabetes, and hy…
-
Mazdutide Shows Strong Efficacy for Type 2 Diabetes and Weight Loss in Chinese Adults
This study highlights the potential of Mazdutide as a highly effective treatment option for type 2 diabetes, particularly in the Chinese adult population, addressing both glycemic control and significant weight manage…
-
Mazdutide Outperforms Dulaglutide in Chinese Adults with Type 2 Diabetes
-
Comprehensive Review Unveils Multidimensional Strategies for Hyperuricemia Management
This comprehensive review underscores the critical need for integrated treatment strategies for hyperuricemia, moving beyond single-modality approaches. By combining the strengths of Western pharmacology, Traditional …
-
Long-Acting GLP-1 Agonists Show Superior Efficacy in Type 2 Diabetes Management
This comprehensive evaluation provides critical evidence supporting the superior efficacy of certain long-acting GLP-1 RAs in managing Type 2 Diabetes, particularly concerning glycemic control and weight reduction. Th…
-
Mazdutide Shows Strong Efficacy and Safety for Weight Loss in Non-Diabetic Adults
This study provides robust evidence supporting Mazdutide as a highly effective and generally safe therapeutic option for overweight and obesity in non-diabetic adults. The substantial and sustained weight loss observe…
-
Mazdutide's Patent Journey: A Dual Agonist for Obesity and Diabetes
-
IBI362 Completes Phase II Trial for Type 2 Diabetes in Chinese Patients
-
Mazdutide Shows Promise for Fatty Liver Disease by Targeting Cellular Stress and Metabolism
This study highlights Mazdutide's multifaceted therapeutic potential for MASLD, demonstrating its ability to simultaneously improve lipid metabolism, reduce inflammation, and alleviate cellular stress. The significant…
-
New Dual Agonist IBI362 Explored for Obesity Treatment in Chinese Patients
The successful completion of this Phase 1/2 trial for IBI362 could significantly impact the landscape of obesity treatment, particularly for the Chinese patient population. If IBI362 demonstrates a favorable safety pr…
-
Mazdutide Explored as Potential Treatment for Alcohol Use Disorder in Phase 2 Trial
If successful, this study could establish Mazdutide as a promising new therapeutic option for Alcohol Use Disorder (AUD), potentially offering a novel mechanism of action (via GLP-1/GIP agonism affecting reward pathwa…
-
Phase 2 Trial Completes Enrollment for Novel Obesity Drug LY3305677 (Mazdutide)
-
Mazdutide Investigated for Treating Polycystic Ovary Syndrome in Obese Women
PCOS is a complex condition with significant unmet medical needs, particularly for obese patients struggling with hyperandrogenism and metabolic dysfunction. If Mazdutide proves effective in reducing FAI, it could rep…
-
IBI362 Pharmacokinetics Explored in Patients with Kidney Impairment
Understanding how renal impairment affects IBI362's pharmacokinetics is critically important for patient safety and treatment efficacy. If kidney function significantly alters drug exposure, dose adjustments will be n…
-
Mazdutide: A Novel Dual Agonist for Significant Weight Loss and Metabolic Improvement
Mazdutide's dual GLP-1R and GCGR agonism offers a unique mechanism that appears to drive superior weight loss and broader metabolic improvements compared to single-target therapies. This comprehensive metabolic benefi…
-
Mazdutide 9 mg Achieves Significant Weight Loss in Obese Chinese Adults
This study provides compelling evidence for the robust efficacy and favorable safety profile of Mazdutide 9 mg as a potent new treatment for obesity, specifically in Chinese adults. These findings are critical for adv…
Research tools
Free, no account — handy when you're working with Mazdutide.
